跳至主要内容
临床试验/NCT00227747
NCT00227747
已完成
3 期

Randomized Phase III Trial Comparing in a Preoperative Schedule the Result of Two Concurrent Chemoradiation Schemes (45 Gy + Capecitabine vs 50 Gy + Capecitabine - Oxaliplatin) on the Rate of Sterilization of the Operative Specimen in Resectable Rectal Carcinomas T3-4 No-2 Mo

UNICANCER68 个研究点 分布在 1 个国家目标入组 598 人2005年11月8日

概览

阶段
3 期
干预措施
capecitabine
疾病 / 适应症
Colorectal Cancer
发起方
UNICANCER
入组人数
598
试验地点
68
主要终点
Rate of complete surgical resection
状态
已完成
最后更新
5年前

概览

简要总结

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving radiation therapy together with combination chemotherapy before surgery may shrink the tumor so it can be removed. It is not yet known whether giving radiation therapy together with capecitabine is more effective with or without oxaliplatin before surgery in treating rectal cancer.

PURPOSE: This randomized phase III trial is studying radiation therapy, capecitabine, and oxaliplatin to see how well they work compared to radiation therapy and capecitabine in treating patients who are undergoing surgery for stage II or stage III rectal cancer.

详细描述

OBJECTIVES: Primary * Compare the efficacy of neoadjuvant chemoradiotherapy comprising radiotherapy and capecitabine with vs without oxaliplatin followed by total mesorectal excision, in terms of the rate of complete surgical resection, in patients with resectable stage II or III rectal cancer. Secondary * Compare overall and disease-free survival of patients treated with these regimens. * Compare clinical tumor response in patients treated with these regimens. * Compare acute and late toxicity of these regimens in these patients. * Determine biological parameters that predict tumor response and treatment-related toxicity in patients treated with these regimens. * Compare sphincter preservation and function in patients treated with these regimens. OUTLINE: This is a randomized, controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo radiotherapy once daily 5 days a week and receive capecitabine once daily 5 days a week in weeks 1-5. * Arm II: Patient undergo radiotherapy and receive capecitabine as in arm I. Patients also receive oxaliplatin once weekly in weeks 1-5. All patients undergo total mesorectal excision 6 weeks after completion of chemoradiotherapy. PROJECTED ACCRUAL: A total of 590 patients will be accrued for this study.

注册库
clinicaltrials.gov
开始日期
2005年11月8日
结束日期
2013年7月15日
最后更新
5年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
UNICANCER
责任方
Sponsor

入排标准

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Radiothérapie + Xelox

干预措施: capecitabine

Radiothérapie + Xelox

干预措施: oxaliplatin

Radiothérapie + Xelox

干预措施: conventional surgery

Radiothérapie + Xelox

干预措施: neoadjuvant therapy

Radiothérapie + Xelox

干预措施: radiation therapy

Radiothérapie + Capécitabine

干预措施: capecitabine

Radiothérapie + Capécitabine

干预措施: conventional surgery

Radiothérapie + Capécitabine

干预措施: neoadjuvant therapy

Radiothérapie + Capécitabine

干预措施: radiation therapy

结局指标

主要结局

Rate of complete surgical resection

次要结局

  • Overall survival
  • Disease-free survival
  • Sphincter preservation
  • Sphincter function
  • Biological parameters that predict tumor response and treatment-related toxicity
  • Acute and late toxicity

研究点 (68)

Loading locations...

相似试验